The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 30, 2024

Filed:

Sep. 18, 2019
Applicant:

Kunming Institute of Zoology Chinese Academy of Sciences, Kunming, CN;

Inventors:

Yonggang Yao, Kunming, CN;

Rongcan Luo, Kunming, CN;

Guiyu Li, Kunming, CN;

Lingyan Su, Kunming, CN;

Jing Yang, Kunming, CN;

Dengfeng Zhang, Kunming, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/192 (2006.01); A61K 31/13 (2006.01); A61K 31/24 (2006.01); A61K 31/445 (2006.01); A61K 31/55 (2006.01); A61K 31/702 (2006.01); A61P 25/16 (2006.01); A61P 25/28 (2006.01);
U.S. Cl.
CPC ...
A61K 31/192 (2013.01); A61K 31/13 (2013.01); A61K 31/24 (2013.01); A61K 31/445 (2013.01); A61K 31/55 (2013.01); A61K 31/702 (2013.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01);
Abstract

A use of Gemifibrozil and a pharmaceutically acceptable salt, ester, or stereoisomer thereof in the preparation of a medicament for the treatment and/or prevention of a neurodegenerative disease. The neurodegenerative disease is selected from Alzheimer's disease, Parkinson's disease, Huntington's disease, or amyotrophic lateral sclerosis. Further provided is a pharmaceutical composition for treating and/or preventing a neurodegenerative disease, wherein the pharmaceutical composition comprises Gemifibrozil, or a pharmaceutically acceptable salt, ester, or stereoisomer thereof, and, preferably, the pharmaceutical composition further comprises one or a plurality of pharmaceutically acceptable carriers. Further provided is a use of the pharmaceutical composition comprising Gemifibrozil, or a pharmaceutically acceptable salt, ester, or stereoisomer thereof in the preparation of a medicament for the treatment and/or prevention of a neurodegenerative disease.


Find Patent Forward Citations

Loading…